Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Other Accumulated Expenses (2016 - 2025)

Mimedx's Other Accumulated Expenses history spans 15 years, with the latest figure at $5.8 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 28.47% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $5.8 million, up 28.47%, while the annual FY2025 figure was $5.8 million, 28.47% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $5.8 million at Mimedx, up from $4.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $5.8 million in Q4 2025 and bottomed at $1.6 million in Q1 2022.
  • The 5-year median for Other Accumulated Expenses is $2.0 million (2022), against an average of $2.7 million.
  • The largest annual shift saw Other Accumulated Expenses plummeted 31.42% in 2021 before it surged 126.92% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.6 million in 2021, then increased by 17.19% to $1.8 million in 2022, then surged by 57.8% to $2.9 million in 2023, then soared by 55.74% to $4.5 million in 2024, then increased by 28.47% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Other Accumulated Expenses are $5.8 million (Q4 2025), $4.4 million (Q3 2025), and $3.4 million (Q2 2025).